Showing 76–100 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Van Deun A, Decroo T, Kuaban C, Noeske J, Piubello A, et al.
…llected from patients starting one of the shorter treatment regimens (STRs) for multidrug-resistant tuberculosis (MDR-TB) in Bangladesh, Niger or Cameroon. OBJECTIVE: To estimate the effect of either a gatifloxacin (GFX), moxifloxacin (MFX) or levofloxacin (LVX) based STR on bact…
Vibol Iem, Sakhone Suthepmany, Vongkham Inthavong, Anousone Sisouvanh, Khamloun Choumlivong, et al.
…is (MDR/RR-TB) was introduced under the TDR Short, all-Oral Regimens for Rifampicin-resistant Tuberculosis (ShORRT) initiative. **METHODS:** A retrospective and prospective comparative cohort study was conducted across five drug-resistant tuberculosis treatment centres from Janu…
Nusrat Shafiq, Ashok Kumar, Vikram Vohra, Gopal Krishan Khuller, Manjula Singh, et al.
**BACKGROUND:** Clofazimine, an antimycobacterial agent, has demonstrated efficacy in reducing the treatment duration for MDR TB. **OBJECTIVES:** To determine whether a 16 week clofazimine-based regimen is non-inferior to the standard 24 week regimen for drug-susceptible pulmona…
Tasneen R, Garcia A, Converse PJ, Zimmerman MD, Dartois V, et al.
…rine models of tuberculosis were used to test whether novel regimens replacing rifapentine and isoniazid with bedaquiline and another drug would maintain or increase the sterilizing activity of the regimen. In BALB/c mice, replacing rifapentine in the PZM backbone with bedaquilin…
Arnold Louie, Michael Neely, Sarah Kim, Charles A Scanga, JoAnne L Flynn, et al.
… There has been little prior effort to identify combination regimens that employ new or repurposed drugs in a rational way. **METHODS AND FINDINGS:** Our group developed a pathway to combine agents to achieve this end. This pathway starts with standard baseline evaluations (e.g.…
Malaisamy Muniyandi, Karikalan Nagarajan, Karthick Chelvanayagam, Kavitha Rajsekar, Kirti Tyagi, et al.
…s resistant to rifampicin (RR-TB) are limited and available regimens are often lengthy and poorly tolerated. However, following recent evidence from the TB PRACTECAL trial, countries are considering programmatic adoption of six-month, all-oral treatment regimen such as bedaquilin…
Rupani MP, Dave JD, Parmar VB, Singh MP, Parikh KD
…iscontinuation of multidrug-resistant tuberculosis (MDR-TB) regimens have not been studied in Gujarat. We aimed to find out the adverse drug reactions (ADRs) and predictors for discontinuation of MDR-TB regimens. Methods We conducted this cross-sectional study in Bhavnagar distri…
Fekadu G, Wang Y, You JHS
BACKGROUND: Recent clinical findings reported improvement in the treatment outcomes of highly resistant TB (HDR-TB) with the pretomanid (Pa) based regimen. This study aimed to evaluate the cost-effectiveness of the Pa-based regimen for HDR-TB treatment from the perspective of the…
Song L, Zhang Y, Sun F, Lan Y, Tong J, et al.
…atment have led to concerns about hepatotoxicity in shorter regimens. We evaluated hepatotoxicity in two novel regimens against the standard shorter regimen recommended by the World Health Organization (WHO). Methods Participants from the TB-TRUST and TB-TRUST plus trials were as…
Van Deun A, Decroo T, Kya Jai Maug A, Hossain MA, Gumusboga M, et al.
…two months), but had little impact on rifampicin-throughout regimens: (6 months, new cases; 3.8%; OR 0.8, 95%CI:0.3,2.8; 8 months, retreatment cases: 7.3%, OR 1.8; 95%CI:1.3,2.6). Rr was missed in 7.6% of randomly selected "Hr" strains. Acquired Rr was frequent among recurrences …
Phillips PPJ, Van Deun A, Ahmed S, Goodall RL, Meredith SK, et al.
…to 84.2% across five alternative outcomes. However, between-regimens results did not exceed 1.3% in favor of the long regimen (95% CI upper bound 10.1%), similar to the primary efficacy results from the trial. Considering only Definite or Probable FoR events, there was weak evide…
Ardhianto D, Suharjono, Soedarsono, Fatmawati U
…ion. The aim was to study the differences in the use of BDQ regimens to the lengthening of the QTc interval and to study risk factors (diabetes, hypokalemia, sex, BMI, and age) in BDQ regimen. Methods This study was an observational retrospective study with a total sampling metho…
Van Deun A, Decroo T, Piubello A, de Jong BC, Lynen L, et al.
…th Organization guidelines for the formulation of treatment regimens for multidrug-resistant tuberculosis (MDR-TB) pay too little attention to the microbiological activity of anti-tuberculosis drugs. Here, we draw lessons from the pioneering work done on shorter MDR-TB treatment …
Arinaminpathy N, Gomez GB, Sachdeva KS, Rao R, Parmar M, et al.
…re is increasing interest in future, highly-potent 'pan-TB' regimens against tuberculosis (TB), that may be equally effective in both drug-susceptible and rifampicin-resistant (RR) forms of TB. Taking the example of India, the country with the world's largest burden of TB, we sho…
Gauri Goswami, Pradeep Nirala, Rajeev Tandon, Pulkit Kalra, Mohammed Tariq, et al.
…omorbidities often necessitate alternative non-standardized regimens. Objective The aim of the study was to identify and evaluate the use, rationale, and outcome of non-standardized ATT regimens in patients with drug-sensitive tuberculosis. Method Our prospective observational st…
Mojisola Clara Hosu, Lindiwe Modest Faye, Teke Apalata
…time ranged from 29 to 59 days. Patients on short treatment regimens converted significantly faster than those on long regimens (= 7.55 × 10), with 90% of short-regimen patients achieving favorable outcomes compared to 52% in the long regimen group (= 0.0000040). Spearman co…
Modongo C, Wang Q, Dima M, Matsiri O, Kgwaadira B, et al.
… patients concomitantly receiving rifampicin- and DTG-based regimens under programmatic conditions in Botswana. The outcomes of interest were successful TB treatment and viral load suppression. We used multivariable logistic models to determine predictors for each outcome of inte…
Ginenus Fekadu, Tadesse Tolossa, Firomsa Bekele, Xiaohan Chen, Yan He, et al.
…line (Bdq), has led to the development of shorter treatment regimens. This systematic review and meta-analysis aimed to examine the impact of these regimens, synthesising data from recent clinical trials and observational studies. **METHODS:** We searched multiple databases, inc…
Ur Rehman O, Fatima E, Ali A, Akram U, Nashwan A, et al.
…ire treatment with newer drugs. Bedaquiline based treatment regimens have been used in patients who are diagnosed with drug resistant tuberculosis. The aim of this study is to assess the efficacy and safety profile of bedaquiline-based treatment regimens using a systematic review…
Rodriguez CA, Lodi S, Horsburgh CR, Mitnick CD, Bastard M, et al.
Clarity about the role of delamanid in longer regimens for multidrug-resistant TB is needed after discordant Phase IIb and Phase III randomized controlled trial results. The Phase IIb trial found that the addition of delamanid to a background regimen hastened culture conversion; …
Gualano G, Musso M, Mencarini P, Mosti S, Cerva C, et al.
… of MDR-TB has been revolutionized by all oral anti-TB drug regimens that are likely to improve adherence and treatment outcomes. These regimes include bedaquiline (B), pretomanid (P), and linezolid (L) (BPaL), and moxifloxacin if resistance to fluoroquinolones is not detected (B…
Bada FO, Blok N, Okpokoro E, Dutt S, Akolo C, et al.
…d treatment success rates of 52-66% while shorter treatment regimens have reported success rates of 85% and above. In addition, replacing the second-line injectable agent in a shorter treatment regimen with bedaquiline has been found to further improve treatment success in patien…
Anaam MS, Alrasheedy AA
…rd 6-month regimen was lower than that with the previous TB regimens. However, more efforts are needed to decrease TB recurrence rates further and achieve a durable cure for TB. In addition, healthcare professionals and TB control programs should consider potential risk factors o…
Shah R, Khakhkhar T, Modi B
…lysis, we compared the efficacy and safety of different TPT regimens. We searched PubMed, Google Scholar, and medrxiv.org with search terms Tuberculosis Preventive Treatment, TPT, efficacy, safety, and drug regimens for TPT and all RCT, irrespective of age, setting, or co-morbidi…
Avaliani T, Sereda Y, Davtyan H, Tukvadze N, Togonidze T, et al.
Tuberculosis treatment is challenging, especially among people with drug-resistant forms of tuberculosis. The introduction of fully oral modified short treatment regimen has a great potential to shorten duration of treatment, improve safety and ultimately increase treatment succe…